Dupilumab significantly improved eosinophilic oesophagitis outcomes in a 2026 randomized controlled trial, reducing eosinophil counts to safe levels in most patients by 24 weeks regardless of their weight, disease duration, prior treatments, or other allergic conditions. According to Gram Research analysis, benefits were maintained through 52 weeks, making this medicine an effective option for patients who haven’t responded to other treatments.
Researchers tested a new medicine called dupilumab on people with eosinophilic oesophagitis, a painful condition where too many white blood cells build up in the food pipe. According to Gram Research analysis, the drug worked better than a placebo at reducing these cells and improving swallowing in almost every group of patients tested, whether they had other allergies, had tried other treatments before, or had the condition for different lengths of time. The benefits lasted for a full year, making this an important option for people struggling with this difficult-to-treat disease.
Key Statistics
A 2026 randomized controlled trial published in Alimentary Pharmacology and Therapeutics found that dupilumab increased the proportion of patients achieving histological remission (eosinophil counts of 6 or fewer per high-power field) at 24 weeks compared to placebo across all patient subgroups studied.
In the same trial, improvements in swallowing difficulty and endoscopic inflammation scores were maintained at 52 weeks in patients who continued dupilumab treatment, and patients who switched from placebo to dupilumab at week 24 also showed significant improvements.
Dupilumab demonstrated consistent efficacy in eosinophilic oesophagitis patients regardless of demographics, disease duration, prior elimination diet use, concurrent proton pump inhibitor use, or presence of type 2 inflammatory comorbidities like asthma or atopic dermatitis.
The Quick Take
- What they studied: Whether a new medicine called dupilumab could help people with eosinophilic oesophagitis, a condition where too many white blood cells called eosinophils attack the food pipe and make swallowing painful.
- Who participated: Patients with eosinophilic oesophagitis were divided into different groups based on their weight, how long they had the disease, whether they had other allergies or asthma, and what treatments they had tried before. The study looked at how the medicine worked across all these different groups.
- Key finding: At 24 weeks, dupilumab helped significantly more patients get their eosinophil counts down to safe levels compared to placebo, and this improvement stayed strong at 52 weeks. The medicine worked equally well no matter what group patients were in.
- What it means for you: If you have eosinophilic oesophagitis and other treatments haven’t worked well, dupilumab may be a helpful option. However, talk with your doctor about whether this medicine is right for your specific situation, as it works best when prescribed and monitored by a specialist.
The Research Details
This was a randomized controlled trial, which is the gold standard type of medical research. Patients were randomly assigned to receive either dupilumab or a placebo (fake medicine) so researchers could fairly compare how well the real medicine worked. The study followed patients for 52 weeks, or about one year. Researchers divided patients into many different subgroups based on things like their weight, how long they had the disease, whether they had other allergies or asthma, and what treatments they had already tried. This allowed them to see if the medicine worked the same way for everyone or if it worked better for certain types of patients.
The researchers measured three main things to see if the medicine was working. First, they looked at the number of eosinophils (white blood cells) in the food pipe under a microscope. Second, they asked patients questions about how hard it was to swallow food. Third, they looked at the food pipe with a camera to see if the inflammation had improved. These three measurements gave a complete picture of whether the medicine was actually helping.
This study design is important because it shows that dupilumab works not just for one type of patient, but for many different kinds of people with this disease. Previous research might have only tested the medicine in a small group of similar patients. By testing it in many different subgroups, researchers can be more confident that doctors can use this medicine for a wider range of patients. This is especially important for a disease like eosinophilic oesophagitis, where patients often have different backgrounds, different lengths of illness, and different other health conditions.
This study was published in a well-respected medical journal called Alimentary Pharmacology and Therapeutics, which means experts reviewed it before publication. The study was randomized, meaning patients were randomly assigned to groups, which reduces bias. The study lasted a full year, which is long enough to see if benefits last over time. The researchers also looked at what happened when patients who got placebo switched to the real medicine halfway through, which helped confirm the results. However, the exact number of patients in the study was not clearly stated in the abstract, which makes it harder to judge how reliable the results are.
What the Results Show
At 24 weeks, dupilumab helped significantly more patients achieve histological remission, which means their eosinophil counts dropped to 6 or fewer cells per high-power field (the safe level). This improvement happened in every subgroup the researchers looked at, whether patients were overweight or normal weight, whether they had had the disease for a few years or many years, and whether they had other allergies or asthma. The improvements were not just a little bit better than placebo, but substantially better across the board.
At 52 weeks, the benefits stayed strong. Patients who continued taking dupilumab kept their improvements, and patients who had been on placebo for the first 24 weeks and then switched to dupilumab also showed major improvements. This means the medicine continued to work well over the full year of the study. The researchers also measured how much patients’ swallowing improved and how much the inflammation in their food pipe decreased when doctors looked with a camera. Both of these measures showed similar improvements across all patient groups.
What makes this finding especially important is that it worked the same way for almost everyone. Whether a patient had tried elimination diets before, was taking acid-reducing medicines, had had their food pipe stretched by doctors, or had other allergic conditions, dupilumab still helped them. This consistency across different patient types suggests that doctors can confidently offer this medicine to a wide range of people with eosinophilic oesophagitis.
The study also looked at how much patients’ symptoms improved using a questionnaire about difficulty swallowing. Patients on dupilumab reported much better swallowing compared to those on placebo, and this improvement was consistent across all the different patient groups studied. Additionally, when doctors looked at the food pipe with a camera and scored the amount of inflammation they saw, dupilumab patients showed much better improvement than placebo patients. These secondary findings confirm that the medicine not only reduced the number of white blood cells but also made patients feel better and look better on examination.
Previous studies of dupilumab for eosinophilic oesophagitis showed promise, but this study is important because it specifically looked at whether the medicine works equally well for different types of patients. Earlier research sometimes focused on patients without other allergic conditions or patients who hadn’t tried other treatments yet. This new research shows that dupilumab works well even for patients who have tried other treatments, who have other allergies or asthma, or who have had the disease for a long time. This expands the potential usefulness of the medicine beyond what was previously known.
The study abstract does not clearly state how many patients participated, which makes it harder to judge how reliable the results are. The study only lasted one year, so we don’t know if the benefits continue beyond that time. The study was done in a controlled research setting, so results might be slightly different in real-world medical practice. The study looked at many different subgroups, which means some of the smaller groups might have had fewer patients, making those results less certain. Finally, the study did not compare dupilumab to other newer treatments, only to placebo, so we don’t know how it compares to other options doctors might offer.
The Bottom Line
For patients with eosinophilic oesophagitis who have not responded well to other treatments or who have other allergic conditions, dupilumab appears to be an effective option with strong evidence of benefit. The confidence level is high because this was a well-designed randomized controlled trial that showed consistent results across many different patient types. Patients should discuss with their gastroenterologist or allergist whether dupilumab is appropriate for their specific situation, as it is a prescription medicine that requires medical supervision.
This research is most relevant for people who have been diagnosed with eosinophilic oesophagitis and are struggling with swallowing difficulties or have not had good results with other treatments like elimination diets or acid-reducing medicines. It’s also relevant for people who have eosinophilic oesophagitis along with other allergic conditions like asthma, hay fever, or eczema. People without eosinophilic oesophagitis do not need to consider this medicine. Doctors and allergists should care about this research because it helps them understand which patients might benefit most from this treatment option.
Based on this study, patients who start dupilumab can expect to see improvements in their eosinophil counts within 24 weeks (about 6 months). Improvements in swallowing and inflammation visible on examination happen around the same time. These benefits appear to continue and even improve further by 52 weeks (one year). Individual patients may see benefits at different speeds, so it’s important to follow up regularly with your doctor to monitor progress.
Frequently Asked Questions
Does dupilumab work for eosinophilic oesophagitis in people who have tried other treatments before?
Yes, research shows dupilumab improved outcomes in patients regardless of prior treatment history, including those who had tried elimination diets or other therapies. The medicine worked equally well whether patients were treatment-naive or had previous unsuccessful treatments.
How long does it take for dupilumab to help with swallowing problems from eosinophilic oesophagitis?
Improvements in swallowing difficulty appeared within 24 weeks of starting dupilumab in the clinical trial. Benefits continued to improve through 52 weeks, suggesting the medicine works progressively over several months of treatment.
Will dupilumab work if I have asthma or allergies along with eosinophilic oesophagitis?
Research shows dupilumab worked effectively in patients with eosinophilic oesophagitis regardless of whether they had other type 2 inflammatory conditions like asthma, allergic rhinitis, atopic dermatitis, or food allergies. Having these conditions did not reduce the medicine’s effectiveness.
What does it mean when eosinophil counts reach 6 or fewer per high-power field?
This measurement, called histological remission, indicates that the inflammation in your food pipe has improved to a safe level. It’s measured by taking a small tissue sample and looking at it under a microscope to count the white blood cells causing the problem.
How long do the benefits of dupilumab last for eosinophilic oesophagitis?
In this trial, benefits were maintained for the full 52 weeks of study follow-up. However, the study did not look beyond one year, so long-term durability beyond 52 weeks is not yet known from this research.
Want to Apply This Research?
- Track your swallowing difficulty on a scale of 1 to 10 each week, noting specific foods that are harder or easier to swallow. This mirrors the Dysphagia Symptom Questionnaire used in the study and helps you and your doctor see if the medicine is working.
- Set a daily reminder to take your dupilumab injection on schedule, and keep a food diary noting any changes in your ability to eat different textures. This helps you notice improvements and ensures you don’t miss doses that could affect your results.
- Use the app to log your symptoms weekly and share trends with your doctor at each appointment. Track not just swallowing difficulty but also any other symptoms like chest pain or food getting stuck. This long-term tracking helps your doctor decide if the current dose is working or if adjustments are needed.
This article summarizes research findings and should not be considered medical advice. Eosinophilic oesophagitis is a serious medical condition that requires diagnosis and treatment by a qualified healthcare provider. Dupilumab is a prescription medicine that should only be used under direct medical supervision. If you have symptoms of eosinophilic oesophagitis such as difficulty swallowing, chest pain, or food getting stuck, consult your doctor or gastroenterologist. Individual results may vary, and this medicine may not be appropriate for all patients. Always discuss potential benefits and risks with your healthcare provider before starting any new treatment.
This research translation is published by Gram Research, the science division of Gram, an AI-powered nutrition tracking app.